Market Overview:
The global human prothrombin complex market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of hemophilia B, vitamin K deficiency, and other diseases that require prothrombin complex therapy. In addition, the increasing demand for plasma-derived products is also contributing to the growth of this market. The global human prothrombin complex market can be segmented on the basis of type, application, and region. On the basis of type, the market can be divided into 500 IU/vial, 600 IU/vial 1000 IU/vial,, and others. The 1000 IU/vial segment is expected to grow at a higher CAGR than other segments during the forecast period owing to its high efficacy in treating various diseases. On the basis of application,the global human prothrombin complexmarket can be divided into hemophilia B,, vitamin K deficiency,, and others,.
Product Definition:
The human prothrombin complex is a blood clotting factor that is made up of four proteins: prothrombin, thrombin, Factor V and Factor VIII. These proteins work together to help the blood clot properly. The human prothrombin complex is important for preventing excessive bleeding.
500 IU/Vial:
500 IU/Vial, it's usage.
The International units (IU) or international units are a standard measure for the amount of active ingredient in a pharmaceutical product. One unit is defined as the amount of insulin activity that will produce a 3% change in blood glucose.
600 IU/Vial:
600 IU/Vial is used in human prothrombin complex to treat hereditary angioedema, C. difficile infection and acquired coagulation disorders such as post-transplantation. 600 IU/Vial contains vitamin K which helps in blood clotting.
Application Insights:
On the basis of application, the global human prothrombin complex market is segmented into hemophilia B, vitamin K deficiency and others. Hemophilia B held the largest share in 2017 owing to increasing prevalence of this disorder coupled with rising awareness about availability of treatment options. As per WHO estimates, around 50 million men are living with hemophilia worldwide while 1 million are affected by this condition globally.
Vitamin K deficiency is expected to be fastest growing segment over the forecast period due to increasing number of patients suffering from bleeding disorders and bone fractures as a result lack proper knowledge regarding availability treatment facilities coupled with rising awareness programs for detection & prevention is anticipated to increase demand for these complexes during estimated time frame.
Other applications include factor VIII deficiency (severe).
Regional Analysis:
North America dominated the global human prothrombin complex market in terms of revenue share in 2017. This is due to the presence of a large number of pharmaceutical companies that are engaged in developing and commercializing clotting factor concentrates, which forms an important segment within the global market. Moreover, increasing prevalence of coagulation disorders among patients from high-income countries is expected to fuel demand for prothrombin complex concentrate over the forecast period.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure and improving access for patients living in rural areas as well as underdeveloped countries such as India and China. Furthermore, growing medical tourism industry coupled with favorable government initiatives aimed at promoting blood donation will drive demand further. In addition, rapidly expanding medical device manufacturing sector will also contribute towards regional growth during the same period (2018 - 2030).
Growth Factors:
- Increasing incidence of thrombotic disorders: The global human prothrombin complex market is expected to grow at a CAGR of 5.5% during the forecast period owing to the increasing incidence of thrombotic disorders such as deep vein thrombosis (DVT), pulmonary embolism, and myocardial infarction.
- Growing geriatric population: The global human prothrombin complex market is also driven by the growing geriatric population, as this age group is more susceptible to developing thromboembolic diseases.
- Rising demand for prophylactic therapies: There is a rising demand for prophylactic therapies across the globe due to an increase in awareness about the benefits of early diagnosis and treatment among patients and healthcare professionals alike. This is anticipated to boost growth of the human prothrombin complex market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Prothrombin Complex Market Research Report
By Type
500 IU/Vial, 600 IU/Vial, 1000 IU/Vial, Others
By Application
Hemophilia B, Vitamin K Deficiency, Others
By Companies
Takeda, CSL, Grifols, Octapharma, Hualan Biological, Meheco Xinxing Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Human Prothrombin Complex Market Report Segments:
The global Human Prothrombin Complex market is segmented on the basis of:
Types
500 IU/Vial, 600 IU/Vial, 1000 IU/Vial, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hemophilia B, Vitamin K Deficiency, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda
- CSL
- Grifols
- Octapharma
- Hualan Biological
- Meheco Xinxing Pharma
Highlights of The Human Prothrombin Complex Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 500 IU/Vial
- 600 IU/Vial
- 1000 IU/Vial
- Others
- By Application:
- Hemophilia B
- Vitamin K Deficiency
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Prothrombin Complex Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The human prothrombin complex is a protein that helps to form thromboplastin, which is essential for the clotting of blood.
Some of the major players in the human prothrombin complex market are Takeda, CSL, Grifols, Octapharma, Hualan Biological, Meheco Xinxing Pharma.
The human prothrombin complex market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Prothrombin Complex Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Prothrombin Complex Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Prothrombin Complex Market - Supply Chain
4.5. Global Human Prothrombin Complex Market Forecast
4.5.1. Human Prothrombin Complex Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Prothrombin Complex Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Prothrombin Complex Market Absolute $ Opportunity
5. Global Human Prothrombin Complex Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Prothrombin Complex Market Size and Volume Forecast by Type
5.3.1. 500 IU/Vial
5.3.2. 600 IU/Vial
5.3.3. 1000 IU/Vial
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Prothrombin Complex Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Prothrombin Complex Market Size and Volume Forecast by Application
6.3.1. Hemophilia B
6.3.2. Vitamin K Deficiency
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Prothrombin Complex Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Prothrombin Complex Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Prothrombin Complex Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Prothrombin Complex Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Prothrombin Complex Demand Share Forecast, 2019-2026
9. North America Human Prothrombin Complex Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Prothrombin Complex Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Prothrombin Complex Market Size and Volume Forecast by Application
9.4.1. Hemophilia B
9.4.2. Vitamin K Deficiency
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Prothrombin Complex Market Size and Volume Forecast by Type
9.7.1. 500 IU/Vial
9.7.2. 600 IU/Vial
9.7.3. 1000 IU/Vial
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Prothrombin Complex Demand Share Forecast, 2019-2026
10. Latin America Human Prothrombin Complex Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Prothrombin Complex Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Prothrombin Complex Market Size and Volume Forecast by Application
10.4.1. Hemophilia B
10.4.2. Vitamin K Deficiency
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Prothrombin Complex Market Size and Volume Forecast by Type
10.7.1. 500 IU/Vial
10.7.2. 600 IU/Vial
10.7.3. 1000 IU/Vial
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Prothrombin Complex Demand Share Forecast, 2019-2026
11. Europe Human Prothrombin Complex Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Prothrombin Complex Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Prothrombin Complex Market Size and Volume Forecast by Application
11.4.1. Hemophilia B
11.4.2. Vitamin K Deficiency
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Prothrombin Complex Market Size and Volume Forecast by Type
11.7.1. 500 IU/Vial
11.7.2. 600 IU/Vial
11.7.3. 1000 IU/Vial
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Prothrombin Complex Demand Share, 2019-2026
12. Asia Pacific Human Prothrombin Complex Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Prothrombin Complex Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Prothrombin Complex Market Size and Volume Forecast by Application
12.4.1. Hemophilia B
12.4.2. Vitamin K Deficiency
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Prothrombin Complex Market Size and Volume Forecast by Type
12.7.1. 500 IU/Vial
12.7.2. 600 IU/Vial
12.7.3. 1000 IU/Vial
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Prothrombin Complex Demand Share, 2019-2026
13. Middle East & Africa Human Prothrombin Complex Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Prothrombin Complex Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Prothrombin Complex Market Size and Volume Forecast by Application
13.4.1. Hemophilia B
13.4.2. Vitamin K Deficiency
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Prothrombin Complex Market Size and Volume Forecast by Type
13.7.1. 500 IU/Vial
13.7.2. 600 IU/Vial
13.7.3. 1000 IU/Vial
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Prothrombin Complex Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Prothrombin Complex Market: Market Share Analysis
14.2. Human Prothrombin Complex Distributors and Customers
14.3. Human Prothrombin Complex Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Takeda
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. CSL
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Grifols
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Octapharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Hualan Biological
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Meheco Xinxing Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
